1998 Publications

• Papers
• Books and book chapters
• Abstracts

All links listed below will open in a new window. Close the new window to return to this page.

Papers

• Audoly S, D’ Angio L, Saccomani MP, Cobelli C. Global identifiability of linear compartmental models--a computer algebra algorithm. IEEE Trans Biomed Eng. 1998 Jan;45(1):36-47. [T]
• Avogaro A, A Valerio, P Vicini, G Toffolo, C Varagnolo, A Tiengo and C Cobelli. A modeling approach to quantify the direct ketogenic effect of ethanol in humans. Nutrition Research 18: 1521-1532, 1998. [C]
• Barrett PHR. Kinetics of triglyceride rich lipoprotein metabolism; VLDL versus chylomicrons. Atherosclerosis 141: 35-40, 1998. [C]
• Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism. 1998 Apr;47(4):484-92. [T]
• Barrett PHR, KG Parhofer. LDL-apolipoprotein B metabolism following apheresis: Simulation studies of mass changes and tracer kinetics. Metabolism 47: 478-483, 1998. [C]
• Bertoldo A, Vicini P, GM Sambuceti, A A Lammertsma, O Parodi and C Cobelli. Evaluation of compartmental and spectral analysis models of [¹⁸F]FDG kinetics for heart and brain studies with PET. IEEE Trans. Biomed. Eng. 45: 1429-1448, 1998. [C]
• Bonadonna RC, Saccomani MP, Del Prato S, Bonora E, DeFronzo RA, Cobelli C. Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation. 1998 Jul 21;98(3):234-41.
• Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PHR, Huff MW. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. BBA - Lipids and Lipid Metabolism 1998; 1: 63-79. [C]
• Burnett, JR, PHR Barrett, P Vicini, DB Miller, DE Telford, SJ Kleinstiver and MW Huff. The HMG-CoA reductase inhibitor, atorvastatin, enhances the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 18: 1906-1914, 1998. [C]
• Caumo A, Cobelli C. Minimal model estimate of glucose effectiveness: role of the minimal model volume and of the second hidden compartment. Am J Physiol. 1998 Mar;274(3 Pt 1):E573-6. No abstract available.
• Cobelli C, Bettini F, Caumo A, Quon MJ. Overestimation of minimal model glucose effectiveness in presence of insulin response is due to undermodeling. Am J Physiol. 1998 Dec;275(6 Pt 1):E1031-6. [C]
• Cobelli C, Foster DM. Compartmental models: theory and practice using the SAAM II software system. Adv Exp Med Biol. 1998;445:79-101. [D]
• Cobelli C, Caumo A. Using what is accessible to measure that which is not: Necessity of model of system. Metabolism 47: 1009-1035, 1998. [D]
• Colvin PL, Morguchi E, Barrett PHR, Parks JS, Rudel LL. Production rate determines plasma concentration of large high density lipoprotein in non-human primates. J Lipid Res 39: 2076-2085, 1998. [C]
• Dobbins RL, Davis SN, Neal D, Caumo A, Cobelli C, Cherrington AD. Rates of glucagon activation and deactivation of hepatic glucose production in conscious dogs. Metabolism. 1998 Feb;47(2):135-42. [C]
• Dudley MA, Burrin DG, Wykes LJ, Toffolo G, Cobelli C, Nichols BL, Rosenberger J, Jahoor F, Reeds PJ. Protein kinetics determined in vivo with a multiple-tracer, single-sample protocol: application to lactase synthesis. Am J Physiol. 1998 Mar;274(3 Pt 1):G591-8. [C]
• de-Sain van-der-Velden MG, Kaysen GA, Barrett PHR, Stellaard F, Gadellaa MM, Voorbij HA, Reijngoud DJ, Rabelink TJ. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 1998; 53: 994-1001. [C]
• Foster DM. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. Adv Exp Med Biol. 1998;445:59-78. [D]
• Heatherington, AC, P Vicini and H Golde. A Pharmacokinetic / Pharmacodynamic Comparison of SAAM II and PC/WinNonlin Modeling Software. J. Pharm. Sci. 87: 1255-1263, 1998. [T]
• Laine H, Knuuti MJ, Ruotsalainen U, Utriainen T, Oikonen V, Raitakari M, Luotolahti M, Kirvela O, Vicini P, Cobelli C, Nuutila P, Yki-Jarvinen H. Preserved relative dispersion but blunted stimulation of mean flow, absolute dispersion, and blood volume by insulin in skeletal muscle of patients with essential hypertension. Circulation. 1998 Jun 2;97(21):2146-53.
• Lamarche B, Uffelman KD, Steiner G, Barrett PHR, Lewis GF. Analysis of particle size and lipid composition as determinants of the metabolic clearance of human high density lipoproteins in a rabbit model. J. Lipid Res. 39: 1162-1172, 1998. [C]
• Nielsen MF, Basu R, Wise S, Caumo A, Cobelli C, Rizza RA. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake. Diabetes. 1998 Nov;47(11):1735-47. [C]
• Pierce, CH, RL Dills, MS Morgan, P Vicini and DA Kalman. Biological monitoring of controlled toluene exposure. Int. Arch. Occup. Env. Health 71: 433-444, 1998. [C]
• Steinmueller T, Konrad T, Vicini P, Toffolo G, Jonas S, Tullius S, Bechstein WO, Cobelli C, Usadel KH, Neuhaus P. Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. Transplant Proc. 1998 Jun;30(4):1452-3. [C]
• Vicini P, Bonadonna RC, Lehtovirta M, Groop LC, Cobelli C. Estimation of blood flow heterogeneity in human skeletal muscle using intravascular tracer data: importance for modeling transcapillary exchange. Ann Biomed Eng. 1998 Sep-Oct;26(5):764-74. [C]
• Vicini, P, PHR Barrett, C Cobelli, DM Foster and A Schumitzky. Approaches to population kinetic analysis with applications to metabolic studies. Adv. Exp. Med. and Biol. 445: 103-113, 1998. [T] Aguilar-Salinas CA, Barrett PHR, Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis 141: 203-207, 1998. [C]

[top of page]

Books and book chapters

• None published this year.

Abstracts

• Bell, BM, ER De Oliveira, DM Foster, P Vicini. Application of a Laplace-based population analysis method to lipoprotein studies. PharmSci Supplement 1: S519-S520, 1998. [C]
• Burnett JR, Barrett PHR, Vicini P, Miller DB, Telford TE, Kleinstiver SJ, Huff MW. The HMG-CoA reductase inhibitor, atorvastatin, increases the fractional clearance rate of postprandial triglyceride rich lipoproteins. Drugs affecting lipid metabolism (DALM), 1998. [C]
• Burnett JR, Wilcox LJ, Barrett PHR, Newton RS, Huff MW. The HMG-CoA reductase inhibitor atorvastatin decreases the secretion of apolipoprotein B by HepG2 cells. International Conference on Enzymes, Receptors, and Drugs in Obesity and Atherosclerosis, Toronto, Canada, 1998; published in Clin Biochem, 1998. [C]
• Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PHR, Newton RS, Huff MW. HMG-CoA reductase inhibition and hepatic apolipoprotein B secretion in vivo: a comparison of atorvastatin and simvastatin. 23rd Canadian Lipoprotein Conference, Muskoka, Ontario, Canada, 1998. [C]
• Burnett JR, Wilcox LJ, Telford TE, Kleinstiver SJ, Barrett PHR, Newton RS, Huff MW. HMG-CoA reductase inhibition by atorvastatin in vivo decreases hepatic VLDL apoB secretion to a greater extent than simvastatin. American Heart Assoc 1998. [C]
• Lamarche B, Uffelman K, Carpentier A, Steiner G, Barrett PHR, Lewis GF. Triglyceride enrichment of HDL enhances the metabolic clearance of HDL apolipoprotein A-I in healthy humans. Circulation Suppl. 1998, I-34. [C]
• Lamarche B, Uffelman K, Steiner G, Barrett PHR, Lewis GF. HDL from normotriglyceridemic and hypertriglyceridemic human subjects are cleared at similar rates in a hepatic lipase deficient model, the rabbit. Diabetes Suppl, 47: A31, 1998. [C]
• Parhofer KG, Barrett PHR, G,tlich K, Demant T, Schwandt P. Atorvastatin decreases LDL-apoB production in heterozygous familial hypercholesterolemia. Drugs Affecting Lipoprotein Metabolism, p. 78, Florence, 1998. [C]
• Parhofer KG, Barrett PHR, Schwandt P. LDL apolipoproteinB metabolism: Comparison of two methods to establish kinetic parameters. European Atherosclerosis Society, Geneva, 1998. [C]
• Riches FM, Barrett PHR, Powell MAP, Watts GF. Reduction in visceral adipose tissue improves apoB metabolism in obese men. Aust Diabetes Soc 1998. [C]
• Schaefer EJ, Welty FK, Barrett PHR, Dolnikowski GG, Jenner JL, Lichtenstein AH. Effects of an NCEP Step 2 diet on apolipoprotein B-48 and B-100 metabolism. Circulation Suppl. I-193, 1998. [C]
• Vicini, P, A Schumitzky, BM Bell and C Cobelli. Theory and algorithms for population minimal modeling. Int. Diabetes Monitor 10: A15-A16, 1998. [T]
• Vicini P and C Cobelli. Insulin sensitivity in epidemiological studies: population analysis improves minimal model identification in NIDDM subjects. Diabetes 47: Supplement 1, A151: 589, 1998. [C]
• Welty FK, Lichtenstein AH, Dolnikowski GG, Barrett PHR, Schaefer EJ. Effects of apolipoprotein E genotype on ApoB-48 and ApoB-100 metabolism. Circulation Suppl. I-239, 1998. [C]
• Wilcox LJ, Barrett PHR, Newton RS, Huff MW. The ACAT inhibitor CI-1011 inhibits apoB secretion from HepG2 cells: an effect associated with enhanced rapid intracellular apoB degradation and decreased MTP expression. Circulation Suppl. I-193, 1998. [C]

[top of page]